Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04987996
Title GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors Providence Health & Services
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.